



Regd. Office: No. 201 Devavrata, Sector 17, Vashi, Navi Mumbai 400 705.
Corp. Office: "Strides House", Billekahalli, Bannerghatta Road, Bangalore-560 076.

**UNAUDITED CONSOLIDATED FINANCIAL RESULTS
FOR THE QUARTER ENDED MARCH 31, 2009**

Rs.in Lakhs

Sl. No.	Particulars	UNAUDITED	UNAUDITED	AUDITED
		3 Months ended 31.03.2009	3 Months ended 31.03.2008	12 months ended 31.12.2008
1	(a) Net Sales / Income from Operations	28,425.77	20,697.76	102,033.10
	(b) Other Operating Income	737.20	3,076.82	10,604.11
	Total Income	29,162.97	23,774.58	112,637.21
2	Expenditure			
	(a) (Increase) / decrease in stock in trade & work in progress	(1,491.91)	(843.49)	(3,562.87)
	(b) Consumption of raw materials	12,313.74	8,200.73	40,117.23
	(c) Purchase of traded goods	4,192.88	2,345.53	15,845.82
	(d) Employees cost	4,163.73	4,223.46	18,000.55
	(e) Depreciation	1,009.95	1,038.69	4,006.38
	(f) Other Expenditure	5,746.79	5,434.81	24,669.38
	Total Expenditure	25,935.18	20,399.73	99,076.49
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	3,227.79	3,374.85	13,560.72
4	Other Income (net)	-	6,167.35	25,133.26
5	Profit before Interest & Exceptional Items (3+4)	3,227.79	9,542.20	38,693.98
6	Interest	1,940.80	1,786.11	8,469.75
7	Profit after Interest but before Exceptional Items (5-6)	1,286.99	7,756.09	30,224.23
8	Exceptional Items			
	- Exchange Fluctuation loss (net)	1,272.82	1,980.38	6,698.97
	- Impairment in investments	-	-	16,559.43
	- Changes in fair value of Options embedded in FCCBs	(1,089.35)	-	(4,522.15)
9	Profit from ordinary activities before tax (7-8)	1,103.52	5,775.71	11,487.98
10	Tax Expenses	81.73	361.08	1,079.38
11	Net Profit from ordinary activities after tax (9-10)	1,021.79	5,414.63	10,408.60
12	Extraordinary Item	-	-	-
13	Net Profit for the period (11-12)	1,021.79	5,414.63	10,408.60
	(a) Share of Minority Interest	(26.39)	155.26	(387.78)
	(b) Share in associate	-	-	-
14	Consolidated Profit after Minority Interest & Share from Associates	1,048.18	5,259.37	10,796.38
15	Paid-up Equity Share Capital (Face value of Rs.10/-each)	4,005.00	3,900.43	4,005.00
16	Reserves excluding revaluation reserves			32,441.12
17	Basic & Diluted EPS (Rs.) (Not Annualised)			
	(a) Basic EPS	2.40	14.35	26.91
	(b) Diluted EPS	2.40	10.63	24.70
18	Aggregate of Public shareholding :			
	(a) Number of shares	29,707,086	30,916,911	29,707,086
	(b) Percentage of shareholding	74.17%	79.27%	74.17%
	Promoters and Promoter group shareholding :			
	(a) Pledged / Encumbered			
	- Number of shares	6,896,000	-	-
	- Percentage of shareholding	17.22%	-	-
	(b) Non Pledged / Encumbered			
	- Number of shares	3,446,928	-	-
	- Percentage of shareholding	8.61%	-	-

Notes :

- Pursuant to the provisions of clause 41 of the listing agreement, the Company has opted to publish only the Consolidated results. The standalone results of the Company can be viewed on the Company's website www.stridesarco.com, or on the websites of BSE (www.bseindia.com) or NSE (www.nseindia.com).
- The above Consolidated results for the quarter ended March 31, 2009 were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on April 24, 2009. The Statutory Auditor's have carried out limited review for the Quarter ended March 31, 2009.
- The Company early adopted Accounting Standard 30 *Financial Instrument: Recognition and Measurement* during the year ended December 31, 2008. Consequently, the net profits for the year ended December 31, 2008 includes Rs.14,077.80 lakhs on adjustment made in pursuance of the said Standard.
- On April 13, 2009, the Board of Directors of the Company, subject to corporate, regulatory, statutory and other approvals, granted approval for reorganisation of the Company's business into 3 separate entities ; i) Specialty Pharmaceuticals, ii) Pharmaceuticals and iii) Research and Development with effect from January 1, 2009.
- During the quarter ended March 31, 2009 the Company had the following transactions related acquisition and restructuring:
 - Pharmasave Australia Pty Ltd, Australia became a subsidiary of the Company w.e.f January 15, 2009 consequent to acquisition made by Ascent Pharmahealth Limited, Australia, a subsidiary of Linkace Limited, Cyprus, a wholly owned subsidiary of the Company.
 - In June 2008, Starsmore Limited, a subsidiary of the Company entered into a Put & Call Option agreement for sale of the remaining 49% shareholding in Lakerose Limited to Aspen for agreed multiple of earnings for the year ending June 30, 2009. Consequently, the Latin American venture have not been consolidated effective July 1, 2008.
 - A share purchase agreement has been entered into by Ascent Pharmahealth Limited, Australia a subsidiary of Linkace Limited, Cyprus, to acquire Green Cross Pharma Pte Ltd., for a maximum consideration of SG\$ 4.20 Mio. This transaction has been concluded on April 7, 2009.
- The Company has granted 300,000 options under the Strides Arcolab ESOP-2008 (Director) at Rs. 59.00 per option (exercise price) to few Directors of the Company and 100,000 options under the Strides Arcolab ESOP-2008 at Rs. 59.00 per option (exercise price) to an eligible employee of the Company.
- Exchange fluctuation loss (net) is on account of restatement of foreign currency convertible bonds, External Commercial Borrowings and losses on forward exchange contracts net of exchange losses attributed to loans that have been designated as hedging instruments against Net Investments in foreign operation.
- The Company operates exclusively in the Pharmaceuticals business segment and as such there is no reportable segment information as per Accounting Standard 17.
- Investor grievances received and disposed off during the quarter ended March 31, 2009
 - Pending complaints at the beginning of the quarter - Nil
 - No. of Complaints received - 13
 - Complaints disposed - 13
 - Complaints unresolved - Nil
- Previous quarter's have been recast / restated wherever necessary to conform to the current quarter's classification.

For and on behalf of the Board

**Arun Kumar
Vice Chairman & Managing Director**

**Mumbai
April 24, 2009**